Table 1.
Summary of the main clinical trials with studies on drugs for the treatment of Chagas disease.
| NCT Number | Acronym | Status | Interventions | Phases | Estimated Enrollment | Funded By | Locations |
|---|---|---|---|---|---|---|---|
| NCT02625974 | CHICO | Active, not recruiting | Nifurtimox (Lampit, BAYA2502), Placebo | Phase 3 | 330 participants | Industry | Argentina, Bolivia, Colombia |
| NCT03334838 | Completed | Nifurtimox (Lampit, BAYA2502) | Phase 1 | 36 participants | Industry | Argentina | |
| NCT03350295 | Completed | Nifurtimox (Lampit, BAYA2502) | Phase 1 | 48 participants | Industry | Argentina | |
| NCT02606864 | Completed | Nifurtimox (BAYa2502) | Phase 1 | 36 participants | Industry | Argentina | |
| NCT01927224 | Completed | Nifurtimox (BAYa2502) | Phase 1 | 37 participants | Industry | Argentina | |
| NCT03892213 | Completed | Benznidazole, E1224 | Phase 1 | 28 participants | Other | Argentina | |
| NCT03587766 | FEXI12 | Completed | Fexinidazole, Placebo Oral Tablet | Phase 2 | 45 participants | Other | Spain |
| NCT01377480 | STOP CHAGAS | Completed | Posaconazole, Placebo for posaconazole, Benznidazole | Phase 2 | 120 participants | Industry | Argentina, Chile, Colombia, Guatemala, Mexico, Spain |
| NCT01162967 | CHAGASAZOL | Completed | Benznidazole, Posaconazole | Phase 2 | 78 participants | Other | Spain |
| NCT02154269 | Completed | Treatment with G-CSF (Granulocyte colony stimulating factor), Placebo saline | Phase 2 | 70 participants | Other | Brazil | |
| NCT02386358 | TRAENA | Completed | Benznidazole, Placebo | Phase 3 | 910 participants | Other | Argentina |
| NCT00123916 | BENEFIT | Completed | Benznidazole, Placebo | Phase 3 | 2854 participants | Other | Argentina, Bolivia, Brazil, Colombia, El Salvador |
| NCT00323973 | Completed | Bisoprolol | Phase 3 | 500 participants | Other | Colombia | |
| NCT01755403 | CINEBENZ | Completed | Benznidazole | Phase 4 | 52 participants | Other | Spain |
| NCT01549236 | Pop PK Chagas | Completed | Benznidazole 12,5mg or 100mg | Phase 4 | 80 participants | Other | Argentina |
| NCT01557140 | Completed | RASi plus carvedilol | Phase 4 | 42 participants | Other | Brazil | |
| NCT03981523 | TESEO | Recruiting | Benznidazole, Nifurtimox | Phase 2 | 450 participants | Other, NIH | Bolivia |
| NCT03704181 | COACH | Recruiting | Colchicine 0.5 MG twice day for one year, Placebo Oral Tablet | Phase 2 | 60 participants | Other | Brazil |
| NCT04024163 | Recruiting | Benznidazole | Phase 3 | 164 participants | Industry, Other | Argentina, Bolivia, Colombia | |
| NCT00875173 | STCC | Recruiting | Selenium, Placebo (for Selenium) | Phase 3 | 130 participants | Other | Brazil |
| NCT03672487 | BETTY | Recruiting | Benznidazole, Placebo Oral Tablet | Phase 3 | 600 participants | Other | United States, Argentina |
| NCT03193749 | ATTACH | Recruiting | Amiodarone Hydrochloride, Placebo Oral Tablet | Phase 3 | 200 participants | Other | Colombia |
| NCT01650792 | CLINICS | Recruiting | Aspirin | Phase 4 | 500 participants | Other, NIH | Brazil |
| NCT04023227 | PARACHUTE-HF | Recruiting | Sacubitril/valsartan, Enalapril | Phase 4 | 900 participants | Industry | Argentina, Brazil |
| NCT01489228 | Unknown status | E1224, Benznidazole, Placebo | Phase 2 | 230 participants | Other/Industry | Bolivia | |
| NCT03191162 | MULTIBENZ | Unknown status | Benznidazole | Phase 2 | 240 participants | Other | Argentina, Brazil, Colombia, Spain |
| NCT03378661 | BENDITA | Unknown status | Benznidazole, E1224, E1224 Placebo, Benznidazole Placebo | Phase 2 | 210 participants | Other | Bolivia |
| NCT02498782 | Unknown status | Fexinidazole, Placebo | Phase 2 | 140 participants | Other | Bolivia | |
| NCT02369978 | CHICAMOCHA-3 | Unknown status | Nifurtimox, Benznidazole, Placebo | Phase 2, Phase 3 | 500 participants | Other | Colombia |